fbpx Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science.

Pfizer & BioNTech Pfizer, BioNTech Seek FDA EUA for COVID-19 Vaccine Candidate; Berkeley Lights Announces Pricing of Public Offering; InterVenn Bags $34M

  • 2020-11-25T20:00:00.000+0000
  • California
  • Author: Lauren Panetta

11/25/20 – BioSpace

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

11/24/20 – San Diego Business Journal

Rady Children’s Hospital Receives $1M to Expand 3D Printing

11/24/20 – FierceBiotech

Hoping for an endgame, GSK kick-starts phase 3 RSV vaccine trial in pregnant women

11/24/20 – FierceBiotech

Twist Bioscience's COVID-19 'nanobodies,' inspired by llamas, show promise in hamsters

11/23/20 – The San Diego Union-Tribune

Maravai LifeSciences raises $1.62 billion in upsized stock offering

11/23/20 – FierceBiotech

Schrödinger's in-house pipeline helps fetch $2.7B molecule discovery deal with BMS

11/23/20 – FierceBiotech

FDA approves Hologic's 2-in-1 HIV test for diagnosis, viral load

11/20/20 – Stat News

Pfizer, BioNTech submit formal application to FDA to authorize Covid-19 vaccine

11/20/20 – FierceBiotech

Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast

11/19/20 – Invitae

New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients

11/19/20 – Epic Sciences

Epic Sciences Enters Into Exclusive Licensing Agreement and Collaboration With USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology

11/19/20 – UC San Diego

UC San Diego Leads Research that Earns Gordon Bell Special Prize

11/19/20 – Fierce Biotech

SR One breaks off from GlaxoSmithKline, banks $500M fund

11/19/20 – Berkeley Lights

Berkeley Lights Announces Pricing of Public Offering by Selling Stockholders

11/18/20 – NuVasive

NuVasive Expands Proprietary Porous PEEK Portfolio with Cohere XLIF Interbody

11/18/20 – Pionyr Immunotherapeutics

PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314

11/17/20 – ORIC Pharmaceuticals

ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

11/16/20 – InterVenn Biosciences

InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer

11/16/20 – Travere

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

11/15/20 – Gilead

Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH